WiseGuyRerports.com Presents “Infectious Disease Treatments Market Research Report – Global Forecast Till 2023” New Document to its Studies Database
Infectious diseases are generally caused by pathogenic microorganisms. This includes viruses, bacteria, fungi, and parasites. Its main influential factors are the rising occurrence of infectious disease as well as the increasing inclination towards point-of-care testing. These diseases can be transmitted directly or indirectly, from one individual to the other. The market mainly comprises of biotechnological institutes, medical research laboratories, pharmaceutical companies, market research and consulting service providers as well as research and development (R&D) companies.
The global infectious disease treatments market is estimated to register a CAGR of 7.1% during the forecast period of 2018 to 2023. Market growth of infectious disease treatments occurs as a result of technological advancements in diagnostics for contagious illnesses along with expanding demand. It is believed that low adoption of the treatment and low capita healthcare expenditure in the developing economies may cause a restriction in market growth.
The Americans dominated the global market of infectious disease treatments. This is mainly because of the existence of major market players within the region as well as the ever-increasing infection rates. Following the Americans was Europe. This region stood second owing to the presence of a growing knowledge for the condition, an adequately developed healthcare infrastructure and the element of developed economies within the region. The Middle East & Africa have the lowest share in the global infectious disease treatments market. This is mainly because of the existence of poor economies in the African region. Growth is also restricted in the African region owing to low per capita income and stringent government policies.
- Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc. (U.K)
• AstraZeneca (U.K)
• Novartis AG (Switzerland)
• Sanofi (France)
• Mylan N.V. (U.S.)
Market segmentation is conducted on the basis of type, treatment, and end-users. When it comes to type, the infectious disease treatments market can be classified into bacterial diseases and viral diseases. The viral disease segment is then classified into hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS) and others. The bacterial diseases segment is sub-segmented into bacterial meningitis, tuberculosis (TB) and others.
According to treatment, the market is further split into antifungal drugs, antibacterial and antiviral drugs. Finally, basis end-users, market segmentation is done depending on retail pharmacies as well as hospitals and clinics.
Based on regional analysis, market share and revenue has been studied by taking into consideration the markets in US, Canada, South America, Europe, Western Europe – Germany, France, Italy, and Spain – the UK, Eastern Europe, Rest of Western Europe, Asia Pacific, China, Japan, India, Republic of Korea, Australia, the rest of Asia Pacific region, the United Arab Emirates, Oman, Saudi Arabia, Qatar, Kuwait as well as the rest of the Middle East & Africa.
The Asia Pacific region is anticipated to be the most rapidly growing region in the global market because of the presence of a huge patient population and continuously developing economies such as China and India which possess an expanding healthcare industry. Market growth is further boosted as a result of favorable government policies such as reduced excise and customs duty as well as exemptions in service tax in India that enhance the regional market growth.
Table Of Content:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global By Type
Chapter 7. Global By Treatment
Chapter 8. Global By End Users
Chapter 9. Global By Region
Chapter 10. Company Landscape
Chapter 11 Company Profiles
Chapter 12 MRFR Conclusion
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)